Literature DB >> 28401808

Associations between volume changes and spatial dose metrics for the urinary bladder during local versus pelvic irradiation for prostate cancer.

Oscar Casares-Magaz1, Vitali Moiseenko2, Austin Hopper2, Niclas Johan Pettersson2, Maria Thor3, Rick Knopp2, Joseph O Deasy3, Ludvig Paul Muren1, John Einck2.   

Abstract

BACKGROUND: Inter-fractional variation in urinary bladder volumes during the course of radiotherapy (RT) for prostate cancer causes deviations between planned and delivered doses. This study compared planned versus daily cone-beam CT (CBCT)-based spatial bladder dose distributions, for prostate cancer patients receiving local prostate treatment (local treatment) versus prostate including pelvic lymph node irradiation (pelvic treatment).
MATERIAL AND METHODS: Twenty-seven patients (N = 15 local treatment; N = 12 pelvic treatment) were treated using daily image-guided RT (1.8 Gy@43-45 fx), adhering to a full bladder/empty rectum protocol. For each patient, 9-10 CBCTs were registered to the planning CT, using the clinically applied translations. The urinary bladder was manually segmented on each CBCT, 3 mm inner shells were generated, and semi and quadrant sectors were created using axial/coronal cuts. Planned and delivered DVH metrics were compared across patients and between the two groups of treatment (t-test, p < .05; Holm-Bonferroni correction). Associations between bladder volume variations and the dose-volume histograms (DVH) of the bladder and its sectors were evaluated (Spearman's rank correlation coefficient, rs).
RESULTS: Bladder volumes varied considerably during RT (coefficient of variation: 16-58%). The population-averaged planned and delivered DVH metrics were not significantly different at any dose level. Larger treatment bladder volumes resulted in increased absolute volume of the posterior/inferior bladder sector receiving intermediate-high doses, in both groups. The superior bladder sector received less dose with larger bladder volumes for local treatments (rs ± SD: -0.47 ± 0.32), but larger doses for pelvic treatments (rs ± SD: 0.74 ± 0.24).
CONCLUSIONS: Substantial bladder volume changes during the treatment course occurred even though patients were treated under a full bladder/daily image-guided protocol. Larger bladder volumes resulted in less bladder wall spared at the posterior-inferior sector, regardless the treatment received. Contrary, larger bladder volumes meant larger delivered doses to the superior bladder sector for pelvic RT but smaller doses for local treatments.

Entities:  

Mesh:

Year:  2017        PMID: 28401808      PMCID: PMC6619494          DOI: 10.1080/0284186X.2017.1312014

Source DB:  PubMed          Journal:  Acta Oncol        ISSN: 0284-186X            Impact factor:   4.089


  4 in total

1.  Dosimetric impact of organ at risk daily variation during prostate stereotactic ablative radiotherapy.

Authors:  Lynsey Devlin; David Dodds; Azmat Sadozye; Philip McLoone; Nicholas MacLeod; Carolynn Lamb; Suzanne Currie; Stefanie Thomson; Aileen Duffton
Journal:  Br J Radiol       Date:  2020-01-30       Impact factor: 3.039

2.  A case-control study using motion-inclusive spatial dose-volume metrics to account for genito-urinary toxicity following high-precision radiotherapy for prostate cancer.

Authors:  Oscar Casares-Magaz; Ludvig P Muren; Niclas Pettersson; Maria Thor; Austin Hopper; Rick Knopp; Joseph O Deasy; Michael Væth; John Einck; Vitali Moiseenko
Journal:  Phys Imaging Radiat Oncol       Date:  2018-10-05

3.  Towards spatial representations of dose distributions to predict risk of normal tissue morbidity after radiotherapy.

Authors:  Oscar Casares-Magaz; Vitali Moiseenko; Marnix Witte; Tiziana Rancati; Ludvig P Muren
Journal:  Phys Imaging Radiat Oncol       Date:  2020-08-28

4.  Bladder volume reproducibility after water consumption in patients with prostate cancer undergoing radiotherapy: A systematic review and meta-analysis.

Authors:  Hsiao-Hsuan Chen; Pei-Tzu Lin; Liang-Tseng Kuo; Kun-Sheng Lin; Chiung-Chen Fang; Ching-Chi Chi
Journal:  Biomed J       Date:  2020-11-04       Impact factor: 7.892

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.